Chedraui et al. demonstrated that IL-6 and urokinase-type plasminogen activator levels differed between postmenopausal women with MetS and other women; this difference was associated mainly with metabolic abnormalities [33]. This evidence concerns the gene PLAU and metabolic syndrome.